全文获取类型
收费全文 | 381篇 |
免费 | 39篇 |
国内免费 | 25篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 5篇 |
基础医学 | 18篇 |
口腔科学 | 5篇 |
临床医学 | 102篇 |
内科学 | 44篇 |
皮肤病学 | 2篇 |
神经病学 | 9篇 |
特种医学 | 22篇 |
外科学 | 64篇 |
综合类 | 62篇 |
预防医学 | 18篇 |
眼科学 | 6篇 |
药学 | 51篇 |
中国医学 | 6篇 |
肿瘤学 | 30篇 |
出版年
2024年 | 8篇 |
2023年 | 39篇 |
2022年 | 65篇 |
2021年 | 49篇 |
2020年 | 34篇 |
2019年 | 19篇 |
2018年 | 22篇 |
2017年 | 8篇 |
2016年 | 8篇 |
2015年 | 5篇 |
2014年 | 57篇 |
2013年 | 73篇 |
2012年 | 28篇 |
2011年 | 6篇 |
2010年 | 1篇 |
2009年 | 4篇 |
2008年 | 6篇 |
2007年 | 3篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2003年 | 1篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1989年 | 1篇 |
排序方式: 共有445条查询结果,搜索用时 15 毫秒
441.
AimAngiotensin II type 1 receptor antibody (AT1R Ab) is a non-Human Leucocyte Antigen (HLA) antibody that is maybe associated with early severe kidney transplant rejection and worse graft outcomes. This study aimed to assess the association between AT1R Ab and kidney transplant rejection and graft outcomes.MethodsWe performed a retrospective analysis of all adult kidney transplant recipients in an Australian centre who had an AT1R Ab test between 1 January 2015 to 30 June 2020. AT1R Ab positive patients were compared to AT1R Ab negative patients. Primary outcomes were rejection risk, type and histopathological severity scores. Secondary outcomes were 8-week graft function and graft loss.ResultsOf 965 kidney transplants that were performed during the study period, 73 patients had AT1R Ab tested; 16 (22%) were positive and 57(78%) were negative. Positive patients were on average younger and had higher level of donor-specific HLA antibodies. Rejection occurred in 13 (81%) positive patients and 41 (72%) negative patients (P = 0.45). No significant differences in rejection type or severity were found. HLA mismatch and peak panel reactive antibody ≥80%, but not AT1R Ab, independently predicted rejection. Average (132 vs. 177 mmol/L, P = 0.302) and graft loss were not significantly different between groups.ConclusionThe study found no evidence that AT1R Ab is associated with rejection type, severity or worse graft function. Future studies should assess its relationship with graft outcomes to help complement immunological risk assessment and potentially provide therapeutic options to alter outcomes. 相似文献
442.
《Transfusion and apheresis science》2023,62(3):103700
ObjectiveTo evaluate the association between plasma transfusion and bleeding complications in critically ill patients with an elevated international normalized ratios undergoing invasive procedures.MethodsA retrospective study was conducted to evaluate a consecutive sample of critically ill adult patients undergoing invasive procedures (N = 487) with an international normalized ratio ≥ 1.5 between January 1, 2019 and December 31, 2019. Among the followed patients, 125 were excluded due to incomplete case records and 362 were finally included in this investigation. The exposure was whether plasma had been transfused within 24 h before the invasive procedure. The primary outcome was the occurrence of postprocedural bleeding complications. Secondary outcomes included transfusion of red blood cells within 24 h of the invasive procedure, and additional patient-important outcomes such as mortality and length of stay. Tests were performed with univariate and propensity-matched analyses.ResultsOf the 362 study participants, 99 (27.3 %) received a preprocedural plasma transfusion. In the propensity score-matched analysis, the rate of the occurrence of postprocedural bleeding complications between two groups was not statistically different (OR, 0.605[95 % CI, 0.341–1.071]; P = .085). The rate of postoperative red blood cell transfusion in the plasma transfusion group was higher than that in the non-plasma transfusion group (35.5 % vs 21.5 %; P < .05). No statistically significant difference in mortality was observed between the two groups (29.0 % vs 31.6 %; P = .101).ConclusionsProphylactic plasma transfusion failed to reduce postprocedural bleeding complications in ill critically patients with a coagulopathy. Meanwhile, it was associated with increased red blood cell transfusion after invasive procedures. Findings suggest that abnormal preprocedural international normalized ratios should be managed more conservatively. 相似文献
443.
Soluble HLA-G levels in heart transplant recipients: Dynamics and correlation with clinical outcomes
PurposeTo describe the evolution of the serum levels of soluble HLA-G (s-HLA-G) during the first 12 months after heart transplantation (HT) and to correlate it with clinical outcomes.MethodsObservational study based in a single-center cohort of 59 patients who underwent HT between December-2003 and March-2010. Soluble HLA-G levels were measured from serum samples extracted before HT, and 1, 3, 6 and 12 months after HT. The cumulative burden of s-HLA-G expression during the first post-transplant year was assessed by means of the area under the curve (AUC) of s-HLA-G levels over time and correlated with the acute rejection burden –as assessed by a rejection score–, the presence of coronary allograft vasculopathy (CAV) grade ≥ 1 and infections during the first post-transplant year; as well as with long-term patient and graft survival. Mean follow-up was 12.4 years.ResultsSoluble HLA-G levels decreased over the first post-transplant year (p = 0.020). The AUC of s-HLA-G levels during the first post-transplant year was higher among patients with infections vs. those without infections (p = 0.006). No association was found between the AUC of s-HLA-G levels and the burden of acute rejection or the development of CAV.Overall long-term survival, long-term survival free of late graft failure and cancer-free survival were not significantly different in patients with an AUC of s-HLA-G levels higher or lower than the median of the study population.ConclusionsSoluble HLA-G levels decreased over the first year after HT. Higher HLA-G expression was associated with a higher frequency of infections, but not with the burden of acute rejection or the development of CAV, neither with long-term patient or graft survival. 相似文献
444.
《Transfusion and apheresis science》2023,62(3):103657
Background and objectivesReconstituted fibrinogen concentrate is considered stable for 8–24 h based on product monographs. Given the long half-life of fibrinogen in vivo (3–4 days), we hypothesized that reconstituted sterile fibrinogen protein would remain stable longer than 8–24 h. Extending the expiry date for reconstituted fibrinogen concentrate could decrease wastage and facilitate reconstitution in advance to minimize turnaround times. We performed a pilot study to define the stability of reconstituted fibrinogen concentrates over time.Materials and methodsReconstituted Fibryga® (Octapharma AG) from 64 vials was stored in the temperature-controlled refrigerator (4 °C) for up to 7 days with functional fibrinogen concentration measured serially using the automated Clauss method. The samples were frozen, then thawed and diluted with pooled normal plasma in order for them to be batch tested.ResultsReconstituted fibrinogen samples stored in the refrigerator showed no significant reduction in functional fibrinogen concentration for the entire 7-day study period (p = 0.63). Duration of initial freezing had no detrimental effect on functional fibrinogen levels (p = 0.23).ConclusionFibryga® can be stored at 2–8 °C post-reconstitution for up to one week with no loss in functional fibrinogen activity based on Clauss fibrinogen assay. Further studies with other fibrinogen concentrate formulations and clinical in vivo studies may be warranted 相似文献
445.
目的:对某三级公立医院(以下简称B医院)2015年-2019年医疗运行数据进行分析,通过横向比较了解全院近五年的医疗运行情况.方法:采用描述性统计的方法,选取体现医疗服务、效率和质量等多方面的九项指标,对全院近五年的运行情况进行比较分析.结果:该医院2015年-2019年期间医疗运行整体呈现逐年上升,增长率存在曲折态势... 相似文献